Bibliography
- UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications n patients with Type 2 diabetes (UKPDS33). Lancet (1998) 352:837–853.
- THE DECODE STUDY GROUP: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet (1999) 354:617–622.
- HANEFELD M, FISCHER S, JULIUS U et al.: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia (1996) 39:1577–1583.
- PERFETTI R, MATHUR R, EGAN JM: New insulin secretagogues for the treatment of Type 2 diabetes. Dix Manage Clin. Outcomes (1998) 1:129–135.
- VINAMBERS C, GARCIA-MARTINEZ JA, VILLANUEVA-PENACARRILLO ML etal.: Preservation of nutrient-stimulated biosynthetic activity in pancreatic islets exposed to a meglitinide analogue. Med. Sci Res. (1995) 23:779–780.
- HU S, WANG S, DUNNING BE: Tissue selectivity of nateglinide; study of cardiovascular and I3-cell KATp channels. Diabetes (1999) 48:1;A249.
- HU S, WANG S, FANELLI F etal.: Pancreatic I3-cell KATp channel activity and membrane-binding studies with nateglinide; a comparison with sulfonylureas and repaglinide. PharmacoL Exp. Ther. (2000) 293(2):444–452.
- HIRSCHBERG Y, KARARA AH, PIETRI AO etal.: Improved control of mealtime glucose excursions with coadministration of nateglinide with metformin. Diabetes Care (2000) 23(30):349–353.
- KEILSON L, MATHER S, WALTER YH et al.: Synergistic effects of nateglinide and meal administration on insulin secretion in patients with Type 2 diabetes. I Clin. EndocrinoL Metab. (2000) 85(3):1081–1086.
- KARARA AFT, DUNNING BE, MCLEOD JF: The effect of food on the bioavailability and the pharmacodynamic actions of the insulinotropic actions of the agent nateglinide in healthy subjects. I Clin. PharmacoL (1999) 39:172–179.
- CHOUDHURY S, HIRSCHBERG Y, FILLIPEK R et al.: Single-dose pharmacokinetics od nateglinide in subjects with hepatic cirrhosis. j Clin. PharmacoL (2000) 40(6):634–640.
- TAKESADA H, MATSUDA K, OBTAKE R et al.: Structure determination of metabolites isolated from urine and bile after administration of AY 4166, a novel D-phentlalanine-derivative hypoglycaemicagent. Bioorg. Med. Chem. (1996) 4:1771–1781.
- IKENOUE T, AKIYOSHI M, FUJIRANI S et al.: Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (N RMans-4-isopropylcyclohexyl)-carbonyll-D-Phenylalanine (A-4166). Br j PharmacoL (1997) 120:137–145.
- MORIOMOTO S, MOKUDO O, SAKAMOTO: AY-4166 increases the sensitivity of insulin secretion to glucose in isolated perfused rat pancreas. Harm. Metall Res. (1998) 30:77–79.
- HOLLANDER PA, SCHWARTZ SL, GATLIN MR et al.: Nateglinide, but not gluburide, selectively enhances early insulin release and more effectively controls post-meal glucose excursions with less total insulin exposure.
- HANFIELD M, DICKINSON S, BOUTER KP GUITARD S: Rapid and short-acting insulin secretion with nateglinide controls both prandial and mean glycaemia. Diabetes Care (2000) 23:202–207.
- HORTON ES, FOLLEY J, CLINKIGBEARD C etal.: Nateglinide alone and in combination with metformin improves glycaemic control by reducing mealtime glucose level in type 2 diabetes. Diabetes Care (2000) 23:1660–1665.
- ROSENSTOCK J, GALTIN M, MALLOWS S et al.: Nateglinide improves glycemic control alone and in combination with troglitazone in patients with type 2 diabetes. Diabetes (200) 49\(Suppl. 1):A498